Replies to post #312412 on Innovation Pharmaceuticals Inc (IPIX)

[TheDane]

“ Applicant investigators and institutional officials must not communicate directly with study section members about an application before or after the review. ”

Hope it doesn’t leak!

[JohnLocke101]

Yep. Pretty nice lineup. And if you look at some of the reviewers backgrounds (hint - incl patents), the dots continue to connect.

Good Luck.

[MDCan]

Quite the collection of talent on this committee. Some look like they were hand picked to evaluate B. For instance:

Sean Amberg
Director of Biodefense Initiatives at Kineta, Inc.

I supervised the Anti-Infective Discovery team of 3-6 researchers (B.S., M.S., and Ph.D.) and reported directly to the CSO. I managed the discovery and development of small molecule antivirals and coordinated activities across multiple departments (chemistry, CMC, in vivo biology, and pre-clinical research). Other duties included submitting grant applications to finance these programs, presenting work in peer-reviewed journals and scientific meetings, filing intellectual property claims, identifying promising new avenues of discovery, and evaluating literature and other presentations for business opportunities or partnering candidates. Accomplishments included:

• Discovered and developed lead antiviral candidate for arenavirus-associated disease: optimized biological properties and eliminated liabilities of the chemical scaffold, demonstrated proof-of-concept in animal models, genetically mapped viral determinants of compound sensitivity and demonstrated unique mechanism of action, successfully applied for NIH support of program (SBIR and R01 grants), coordinated several collaborations (academic, government, and BSL-4 labs), and initiated IND-enabling studies

• Discovered broad-spectrum antiviral candidate: utilized parallel high-throughput screening (HTS) against divergent targets to identify broad-spectrum candidates, successfully applied for NIH and DOD support of program

• Discovered antiviral candidate for filovirus-associated disease (Ebola and Marburg): implemented HTS campaign, explored SAR, advanced program to BSL-4 small animal model testing

• Discovered antiviral candidate for LCMV: explored SAR of lead candidate, demonstrated proof-of-concept in mouse model, genetically mapped resistance to unique viral target

• Developed and implemented biological assays for HTS directed against multiple pathogens, including biodefense (arenavirus, filovirus, bunyavirus), respiratory (influenza, RSV), and emerging virus (coronavirus, rhabdovirus) targets